Use and misuse of statins after ACS: Analysis of a prescription database of a community setting of 2,042,968 subjects

European Journal of Preventive Cardiology

Volumn 21, Issue 9, 2014, Pages 1109-1116

  Maggioni, Aldo P ^a   Rossi, Elisa ^b   Cinconze, Elisa ^b   De Rosa, Marisa ^b  

^a ANMCO RESEARCH CENTER   (Italy)

^b CINECA   (Italy)

Author keywords

Acute coronary syndromes; drug; epidemiology; statin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGING; ARTICLE; CAUSE OF DEATH; COMMUNITY ASSESSMENT; COMORBIDITY; DATA BASE; DEPRESSION; DRUG MISUSE; DRUG USE; FEMALE; HOSPITAL DISCHARGE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NEOPLASM; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; VERY ELDERLY; AGE; CEREBROVASCULAR DISEASE; COMMUNITY; COMORBIDITY ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; FOLLOW UP; MALIGNANT NEOPLASTIC DISEASE; SEX DIFFERENCE; CLINICAL PRACTICE; CLINICAL TRIAL; FACTUAL DATABASE; HOSPITALIZATION; MORBIDITY; MULTICENTER STUDY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TRENDS;

ACUTE CORONARY SYNDROME; ADULT; AGED; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MALE; MIDDLE AGED; MORBIDITY; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84906542665     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487313485511     Document Type: Article

References (30)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation. 2011 ; 123: e18 - e209
2. Müller-Nordhorn J, Binting S, Roll S, et al. Editor's choice: an update on regional variation in cardiovascular mortality within Europe. Eur Heart J. 2008 ; 29: 1316-1326
3. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007 ; 356: 2388-2398
4. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008 ; 29: 2909-2945
5. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007 ; 50: e1 - e157
6. Osservatorio Nazionale sull'Impiego dei Medicinali. L'uso dei farmaci in Italia" - Rapporto Nazionale anno 2008. Rome: Il Pensiero Scientifico Editore, 2009.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 ; 344: 1383-1389
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998 ; 339: 1349-1357
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996 ; 335: 1001-1009
10. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366: 1267-1278
11. Rothwell P. External validity of randomised controlled trials: 'To whom do the results of this trial apply?'. Lancet. 2005 ; 365: 82-93
12. Martin K, Begaud B, Latry P, et al. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol. 2004 ; 57: 86-92
13. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005 ; 58: 323-337
14. Poluzzi E, Strahinja P, Lanzoni M, et al. Adherence to statin therapy and patients' cardiovascular risk: a pharmaepidemiological study in Italy. Eur J Clin Pharmacol. 2008 ; 64: 425-432
15. Pickin DM, McCabe CJ, Ramsay LE, et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart. 1999 ; 82: 325-332
16. Chan PSN. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation. 2007 ; 115: 2398-2409
17. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 ; 350: 1495-1504
18. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004 ; 292: 1307-1316
19. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 ; 110: 227-239
20. Jackevicius CA, Anderson GM, Leiter L, et al. Use of the statins in patients after acute myocardial infarction: does evidence change practice?. Arch Intern Med. 2001 ; 161: 183-188
21. Khanderia U, Faulkner TV, Townsend KA, et al. Lipid-lowering therapy at hospital discharge after coronary artery bypass grafting. Am J Health Syst Pharm. 2002 ; 59: 548-551
22. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation. 2001 ; 103: 38-44
23. Ye X, Gross CR, Schommer J, et al. Initiation of statins after hospitalization for coronary heart disease. J Manag Care Pharm. 2007 ; 13: 385-396
24. Birkhead JS, Weston C, Lowe D. Impact of specialty of admitting physician and type of hospital on care and outcome for myocardial infarction in England and Wales during 2004-2005: observational study. BMJ. 2006 ; 332: 1306-1311
25. Doyle F, De La Harpe D, McGee H, et al. Gender differences in the presentation and management of acute coronary syndromes: a national sample of 1365 admissions. Eur J Cardiovasc Prev Rehabil. 2005 ; 12: 376-379
26. Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy. 2001 ; 21: 576-582
27. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002 ; 88: 229-233
28. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998 ; 279: 1458-1462
29. Sung JC, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care. 1998 ; 4: 1421-1430
30. Miller M, Byington R, Hunninghake D, et al. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective randomized evaluation of the vascular effects of Norvasc trial (PREVENT) investigators. Arch Intern Med. 2000 ; 160: 343-347